Ucb SA

XMUN:UNC

Business Description

Sector

Health Care

Industry

Pharmaceuticals

Headquarters

Belgium BE

Employees

9 765

IPO date

Jan 2, 1987

UCB SA is a Belgian biopharmaceutical company that develops and sells prescription medicines for people with serious immune and nervous system diseases. Its main products are treatments for conditions such as epilepsy, Parkinson’s-related movement problems, and immune-mediated disorders like psoriasis, arthritis, and other autoimmune diseases. The company spends heavily on research and clinical testing because its business depends on discovering, proving, and getting approval for new medicines.

UCB makes money by selling these branded drugs to hospitals, pharmacies, and healthcare systems through distributors and direct sales teams. Its customers are mainly doctors, patients, insurers, and public health buyers who decide which medicines are used and reimbursed. Because these drugs are protected by patents and strict regulation, the company’s success depends on medical evidence, regulatory approvals, and the ability to win trust from physicians and payers.

What makes UCB different is that it is a focused drug company rather than a broad healthcare conglomerate. It concentrates on a small number of high-need disease areas where patients often need long-term treatment and where specialized science matters. That makes UCB’s business model tied closely to research, patent protection, and the life cycle of a few key medicines, rather than to large-volume consumer sales.